Notably, inspection of the structure of the receptor showed that the breast cancer mutation is located in the intracellular tyrosine kinase domain adjacent to the activation loop suggesting that it might affect the tyrosine kinase activity of FGFR2 (Fig. 2). This evidence concerns the gene FGFR2 and breast cancer.